Regulatory
Almirall’s Ilumetri (tildrakizumab) Receives NICE’s Provisional Approval for Moderate-To-Severe Plaque
Shots: The approval is based on P-III reSURFACE 1 & reSURFACE 2 studies assessing Ilumetri (tildrakizumab) in 1,800 patients with moderate-to-severe plaque psoriasis across 200 sites WW reSURFACE 1 & […]readmore